Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

Antonio Russo, Giuseppe Badalamenti, Giuseppe Bronte, Elena Fumagalli, Anna Maria Frezza, Margherita Nannini, Maria Abbondanza Pantaleo, Paolo Casali, Delia De Lisi, Mariella Spalato Ceruso, Angelo Paolo Dei Tos, Bruno Vincenzi, Angelo Paolo Dei Tos, Giuseppe Tonini, Daniele Santini, Daniele Santini

Risultato della ricerca: Articlepeer review

7 Citazioni (Scopus)

Abstract

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line.All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits.64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370).A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.
Lingua originaleEnglish
pagine (da-a)69412-69419
Numero di pagine8
RivistaOncotarget
Volume7
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Entra nei temi di ricerca di 'Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis'. Insieme formano una fingerprint unica.

Cita questo